{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:27:09Z","timestamp":1793730429395,"version":"4.6.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001655","name":"Deutscher Akademischer Austauschdienst","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SCHM 3018\/4-1"],"award-info":[{"award-number":["SCHM 3018\/4-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["project number 495891565"],"award-info":[{"award-number":["project number 495891565"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunobiology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.imbio.2026.153233","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T15:56:51Z","timestamp":1787327811000},"page":"153233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A fusion protein of the two tick-derived C5 inhibitors OmCI and RaCI: complete C5 inhibition despite strong complement activation"],"prefix":"10.1016","volume":"231","author":[{"given":"S\u00fcmeyye","family":"Erdemci-Evin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Kaupper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannik","family":"Sichau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Dopler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiba","family":"Ghaboosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Dopler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph Q.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.imbio.2026.153233_bb0005","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12915-015-0203-8","article-title":"Molecular insights into the surface-specific arrangement of complement C5 convertase enzymes","volume":"13","author":"Berends","year":"2015","journal-title":"BMC Biol."},{"key":"10.1016\/j.imbio.2026.153233_bb0010","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/cei.12388","article-title":"A novel method for direct measurement of complement convertases activity in human serum","volume":"178","author":"Blom","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.imbio.2026.153233_bb0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/cr.2009.139","article-title":"Complement and its role in innate and adaptive immune responses","volume":"20","author":"Dunkelberger","year":"2010","journal-title":"Cell Res."},{"key":"10.1016\/j.imbio.2026.153233_bb0020","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1182\/blood-2016-08-732800","article-title":"Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation","volume":"129","author":"Harder","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2026.153233_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01639","article-title":"Different levels of incomplete terminal pathway inhibition by eculizumab and the clinical response of PNH patients","volume":"10","author":"Harder","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imbio.2026.153233_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.parint.2025.103224","article-title":"Tick saliva molecules as potential immunomodulatory therapeutics","volume":"112","author":"Hatta","year":"2026","journal-title":"Parasitol. Int."},{"key":"10.1016\/j.imbio.2026.153233_bb0035","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.imbio.2026.153233_bb0040","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nsmb.3196","article-title":"Structural basis for therapeutic inhibition of complement C5","volume":"23","author":"Jore","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.imbio.2026.153233_bb0045","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","article-title":"Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival","volume":"117","author":"Kelly","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2026.153233_bb0050","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1021\/acs.bioconjchem.6b00369","article-title":"PASylated Coversin, a C5-specific Complement Inhibitor with Extended Pharmacokinetics, shows Enhanced Anti-Hemolytic activity in Vitro","volume":"27","author":"Kuhn","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.imbio.2026.153233_bb0055","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","article-title":"Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study","volume":"133","author":"Kulasekararaj","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2026.153233_bb0060","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s12185-013-1346-4","article-title":"Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry","volume":"97","author":"Lee","year":"2013","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.imbio.2026.153233_bb0065","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study","volume":"133","author":"Lee","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2026.153233_bb0070","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/blood.2020005959","article-title":"Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity","volume":"137","author":"Mannes","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2026.153233_bb0075","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1182\/bloodadvances.2023010817","article-title":"Complement and platelets: prothrombotic cell activation requires membrane attack complex-induced release of danger signals","volume":"7","author":"Mannes","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.imbio.2026.153233_bb0080","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1056\/NEJMra2201664","article-title":"Breakthrough Hemolysis in PNH with Proximal or Terminal Complement Inhibition","volume":"387","author":"Notaro","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.imbio.2026.153233_bb0085","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.4049\/jimmunol.174.4.2084","article-title":"Complement inhibitor of C5 activation from the soft tick Ornithodoros moubata","volume":"174","author":"Nunn","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.imbio.2026.153233_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047245","article-title":"Functional analyses of complement convertases using C3 and C5-depleted sera","volume":"7","author":"Okroj","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.imbio.2026.153233_bb0095","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1073\/pnas.1909973116","article-title":"An Inhibitor of Complement C5 Provides Structural Insights into Activation","volume":"117","author":"Reichhardt","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.imbio.2026.153233_bb0100","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrneph.2016.70","article-title":"Complement in disease: a defence system turning offensive","volume":"12","author":"Ricklin","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.imbio.2026.153233_bb0105","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1182\/blood-2014-12-616300","article-title":"Dissecting complement blockade for clinic use","volume":"125","author":"Risitano","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2026.153233_bb0110","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/ajh.25016","article-title":"Toward complement inhibition 2.0: next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria","volume":"93","author":"Risitano","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.imbio.2026.153233_bb0115","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1182\/blood.2019003399","article-title":"The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria","volume":"135","author":"R\u00f6th","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2026.153233_bb0120","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.imbio.2026.153233_bb0125","doi-asserted-by":"crossref","first-page":"337","DOI":"10.4049\/jimmunol.1600280","article-title":"Structural basis for eculizumab-mediated inhibition of the complement terminal pathway","volume":"197","author":"Schatz-Jakobsen","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.imbio.2026.153233_bb0130","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/imr.13164","article-title":"Protein therapeutics and their lessons: expect the unexpected when inhibiting the multi-protein cascade of the complement system","volume":"313","author":"Schmidt","year":"2023","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.imbio.2026.153233_bb0135","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.pep.2010.12.002","article-title":"Production of biologically active complement factor H in therapeutically useful quantities","volume":"76","author":"Schmidt","year":"2011","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.imbio.2026.153233_bb0140","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/imr.12475","article-title":"Protection of host cells by complement regulators","volume":"274","author":"Schmidt","year":"2016","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.imbio.2026.153233_bb0145","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood.2020007206","article-title":"Complement and the prothrombotic state","volume":"139","author":"Schmidt","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2026.153233_bb0150","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202350817","article-title":"The complement model disease paroxysmal nocturnal hemoglobinuria","volume":"54","author":"Schmidt","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.imbio.2026.153233_bb0155","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/bjh.16305","article-title":"Successful treatment of a PNH patient non-responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan)","volume":"188","author":"Schols","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.imbio.2026.153233_bb0160","doi-asserted-by":"crossref","first-page":"922","DOI":"10.3324\/haematol.2013.093161","article-title":"Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry","volume":"99","author":"Schrezenmeier","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.imbio.2026.153233_bb0165","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/08916934.2017.1423286","article-title":"Gain of function mutant of complement factor B K323E mimics pathogenic C3NeF autoantibodies in convertase assays","volume":"51","author":"Urban","year":"2018","journal-title":"Autoimmunity"},{"key":"10.1016\/j.imbio.2026.153233_bb0170","first-page":"29","article-title":"A new function of the activated third component of complement: binding to C5, an essential step for C5 activation","volume":"34","author":"Vogt","year":"1978","journal-title":"Immunology"}],"container-title":["Immunobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0171298526000793?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0171298526000793?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:31:48Z","timestamp":1793727108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0171298526000793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0171298526000793"],"URL":"https:\/\/doi.org\/10.1016\/j.imbio.2026.153233","relation":{},"ISSN":["0171-2985"],"issn-type":[{"value":"0171-2985","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A fusion protein of the two tick-derived C5 inhibitors OmCI and RaCI: complete C5 inhibition despite strong complement activation","name":"articletitle","label":"Article Title"},{"value":"Immunobiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imbio.2026.153233","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"153233"}}